What is Oncotelic Therapeutics?
Oncotelic Therapeutics operates at the intersection of molecular biology and clinical medicine, focusing on the development of first-in-class RNA therapeutics and small molecule drugs. The company's flagship candidate, OT-101, represents a significant advancement in anti-TGF-RNA technology, having demonstrated notable single-agent efficacy in relapsed and refractory cancer patient populations. Beyond its core oncology focus, the firm has demonstrated versatility by exploring the application of its drug candidates against infectious diseases, including SARS-CoV-2. With a strategic emphasis on rare pediatric cancers, including DIPG, melanoma, and AML, Oncotelic is effectively positioning itself as a high-impact player in the orphan drug market. By maintaining a robust portfolio of rare pediatric designations, the company is well-equipped to navigate the regulatory pathways necessary for bringing life-saving treatments to underserved patient demographics.
How much funding has Oncotelic Therapeutics raised?
Oncotelic Therapeutics has raised a total of $10.8M across 2 funding rounds:
Stock Offering
$10.1M
Stock/Share Issuance
$712K
Stock Issuance/Offering (2021): $10.1M, investors not publicly disclosed
Stock/Share Issuance (2026): $712K, investors not publicly disclosed
Key Investors in Oncotelic Therapeutics
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Oncotelic Therapeutics?
With the successful closure of this major enterprise-level funding, Oncotelic Therapeutics is poised to transition into a more aggressive phase of clinical execution. The strategic allocation of these resources will likely prioritize the advancement of OT-101 through critical trial milestones, while simultaneously bolstering the company's research and development infrastructure. As the firm scales its operations, the focus will remain on optimizing treatment outcomes and improving survival rates for patients with high unmet medical needs. Investors and industry stakeholders will be closely monitoring the company's ability to translate its preclinical and early-stage clinical successes into broader therapeutic applications, potentially setting the stage for future partnerships or commercialization efforts in the global oncology market.
See full Oncotelic Therapeutics company page
